Immuno-Oncology Summit

August 28 - September 1, 2017
Boston, MA, USA

Meet Genedata experts at Immuno-Oncology Summit in Boston, MA, USA

Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals.

To get more information about Genedata solutions, please contact biologics@genedata.com.

Recommended Poster Presentation

Generation, Design and Evaluation of TCR-, TCR mimetic- and CAR-based Therapeutics for Cancer Immunotherapy

Bi- and multi-specific antibodies, Ab-cytokine fusion proteins, non-Ig scaffolds, chimeric antigen receptors (CARs), engineered TCRs and TCR-based bispecific constructs can provide significant advantages for use in cancer immunotherapy. However, as highly engineered molecules they pose new design, engineering, cloning, expression, purification, and analytics challenges. Genedata Biologics enables the automated design, screening, production, and testing of large panels of these candidate therapeutic molecules and includes built-in tools for developability and manufacturability assessments.

Poster Session | August 29–31

Genedata Profiler™: A Collaborative, Scalable, Regulatory Compliant, Computational Infrastructure for Efficient Omic Profiling of Patients in Global Clinical Trials
Nadezda Masloboeva-Siwach, Genedata

Modern clinical trials in the field of immuno-oncology are increasingly biomarker-based, making use of multi-omic profiling of patients for recruitment and monitoring during the trial. Biomarkers that predict cancer patients’ response can be used to selectively target candidates for therapy, boosting the number of patients responding to treatment and significantly increasing the chance of approval of new immuno-oncological therapies.

The increasing use of multi-omic data in oncological clinical trials poses substantial challenges to pharma companies, which must generate timely results from huge volumes of data while ensuring full regulatory (GCP) compliance in this closely scrutinized field. Critical challenges range from moving proven algorithms and analysis pipelines from research into clinically actionable results, through lack of standardization and appropriate GCP controls, to lack of scalability and suitable analytics.

We report here how Genedata Profiler™, an enterprise software platform for multi-omic patient profiling, solves the challenges of processing, analyzing, and managing large volumes of multi-omics data from geographically distributed clinical trials, at scale, and in a regulated (GCP) environment. We also demonstrate that by establishing this infrastructure, organizations can bridge the clinical-research divide to provide harmonization of data, processes, and procedures for translational researchers.

Links:
www.immuno-oncologysummit.com